Synthesis of novel 1-[5-(4-methoxy-phenyl)-[1,3,4]oxadiazol-2-yl]- piperazine derivatives and evaluation of their in vivo anticonvulsant activity

European Journal of Medicinal Chemistry

Volumn 65, Issue , 2013, Pages 276-283

  Harish, Kikkeri P ^a   Mohana, Kikkeri N ^a   Mallesha, Lingappa ^b   Prasanna Kumar, Basavapatna N ^a  

^a UNIVERSITY OF MYSORE   (India)

^b Mysuru   (India)

Author keywords

2,5 Disubstituted 1,3,4 oxadiazole; Anticonvulsant; MES; Sulfonyl chloride

Indexed keywords

1 (2,5 DICHLORO THIOPHENE 3 SULFONYL) 4 [5 (4 METHOXYPHENYL) [1,3,4]OXADIAZOL 2 YL] PIPERAZINE; 1 (3,5 DIMETHYL ISOXAZOLE 4 SULFONYL) 4 [5 (4 METHOXYPHENYL) [1,3,4]OXADIAZOL 2 YL] PIPERAZINE; 1 (4 BROMO 3 METHYL BENZENESULFONYL) 4 [5 (4 METHOXY PHENYL) [1,3,4]OXADIAZOL 2 YL] PIPERAZINE; 1 (4 BROMO BENZENESULFONYL) 4 [5 (4 METHOXY PHENYL) [1,3,4]OXADIAZOL 2 YL] PIPERAZINE; 1 (4 IODO BENZENESULFONYL) 4 [5 (4 METHOXY PHENYL) [1,3,4]OXADIAZOL 2 YL] PIPERAZINE; 1 (4 TERT BUTYL BENZENESULFONYL) 4 [5 (4 METHOXY PHENYL) [1,3,4]OXADIAZOL 2 YL] PIPERAZINE; 1 METHANESULFONYL 4 [5 (4 METHOXY PHENYL) [1,3,4]OXADIAZOL 2 YL] PIPERAZINE; 1 [5 (4 METHOXY PHENYL) [1,3,4]OXADIAZOL 2 YL] 4 (2 NITROBENZENESULFONYL) PIPERAZINE; 1 [5 (4 METHOXY PHENYL) [1,3,4]OXADIAZOL 2 YL] 4 (3 TRIFLUOROMETHYL BENZENESULFONYL) PIPERAZINE; 1 [5 (4 METHOXY PHENYL) [1,3,4]OXADIAZOL 2 YL] 4 (NAPHTHALENE 1 SULFONYL) PIPERAZINE; 1 [5 (4 METHOXY PHENYL) [1,3,4]OXADIAZOL 2 YL] 4 (TOLUENE 4 SULFONYL) PIPERAZINE; 1 [5 (4 METHOXY PHENYL) [1,3,4]OXADIAZOL 2 YL]4 (2 NITRO 4 TRIFLUOROMETHYL BENZENE SULFONYL) PIPERAZINE; 1 [5 (4 METHOXY PHENYL) [1,3,4]OXADIAZOL 2 YL]4 (4 PHENOXY BENZENESULFONYL) PIPERAZINE; 1 [BIPHENYL SULFONYL] 4 (5 (4 METHOXYPHENYL) 1,3,4 OXADIAZOL 2 YL)PIPERAZINE; 4 [4 [5 (4 METHOXY PHENYL) [1,3,4]OXADIAZOL 2 YL] PIPERAZINE 1 SULFONYL] BENZONITRILE; ANTICONVULSIVE AGENT; PHENYTOIN; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; ELECTRIC SHOCK; IN VIVO STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MOUSE; NEUROTOXICITY; NONHUMAN; PHARMACOPHORE; RAT; SEIZURE; STRUCTURE ACTIVITY RELATION;

EID: 84878315396     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.04.054     Document Type: Article

References (16)

1. W. David Loring, Psychiatr. Times XXII (2005) 1-6.
2. H. Hachad, I. Ragueneau-Majlessi, R.H. Levy, Ther. Drug Monit. 24 (2002) 91-103.
3. A. Zarghi, M. Faizi, B. Shafaghi, A. Ahadian, H.R. Khojastehpoor, V. Zanganeh, A. Shafiee, Bioorg. Med. Chem. Lett. 15 (2005) 3126-3129.
4. A. Almasirad, S.A. Tabatabai, M. Faizi, A. Kebriaeezadeh, N. Mehrabi, A. Dalvandi, A. Shafiee, Bioorg. Med. Chem. Lett. 14 (2004) 6057-6059.
5. A. Zarghi, S.A. Tabatabai, M. Faizi, A.P. Ahadian Navabi, V.A. Zanganeh Shafiee, Bioorg. Med. Chem. 15 (2005) 1863-1865.
6. M.S.Y. Khan, R.M. Khan, S. Drabu, Indian J. Heterocycl. Chem. 11 (2001) 119-122.
7. P. Vchal, L.M. Toth, J.J. Hale, L. Yan, S.G. Mills, G.L. Chrebet, C.A. Koehane, R. Hajdu, J.A. Milligan, M.J. Rosenbach, S. Mandala, Bioorg. Med. Chem. Lett. 16 (2006) 3684-3687.
8. P. Vachal, L.M. Toth, Tetrahedron Lett. 45 (2004) 7157-7161.
9. T. Kawano, K. Hirano, T. Satoh, M. Miura, J. Am. Chem. Soc. 132 (2010) 6900-6901.
10. E.V. Zarudnitskii, I.I. Perevak, A.S. Aleksandr, A. Yurchenko, A.A. Tolmachev, Tetrahedron 64 (2008) 10431-10442.
11. K. Ohmoto, T. Yamamoto, M. Okuma, T. Horiuchi, H. Imanishi, Y. Odagaki, K. Kawabata, T. Sekioka, Y. Hirota, S. Matsuoka, H. Nakai, M. Toda, J. Med. Chem. 44 (2001) 1268-1285.
12. R. Braslau, M.O. Anderson, Frank, A. Jimenez, T. Haddad, J.R. Axon, Tetrahedron 58 (2002) 5513-5523.
13. W. Loscher, D. Schmidt, Epilepsy Res. 17 (1994) 95-134.
14. S.N. Pandeya, A.S. Raja, J. Pharm, Pharmaceut. Sci. 5 (2002) 266-271.
15. M.A. Bhat, M.A. Al-Omar, N. Siddiqui, Der Pharma Chemica 2 (2010) 1-10.
16. H.G. Vogel, W.H. Vogel, Drug Discovery and Evaluation. Pharmacological Assays, vol. 2, Springer, Berlin, 1997, pp. 260-261.